On May 11, 2023, Ecofibre (ASX:EOF) has received two patent grant notifications from the US Patent and Trademark Office for treatments related to ovarian cancer and endometriosis.

The granted endometriosis patent also includes therapeutic applications of cannabinoids for fibroids and dysmenorrhea, or period pain.

Ecofibre plans to focus on partnerships to commercialise treatment and management options for gynecological diseases following the granting of the patents.

“Today’s news allows us to move to the next stage of our research program in several key areas for women’s health, and to continue developing new treatment and management options for gynaecological disorders,” said Ecofibre CEO Eric Wang.